Here, we further explored the role of DAC maintenance therapy with serial qRTPCR and flow cytometry MRD monitoring in CBF‐AML patients who completed FLAG‐based regimen with persistent positive qRTPCR or those with abbreviated induction/consolidation courses. The gene discussed is CEBPZ; the disease is acute myeloid leukemia.